PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, data analytics, and AI data processing for the healthcare and life sciences industries, announced that it will sponsoring and participating at the 2024 MUSE Executive Institute, being held Jan 7th-9th, 2024 at The Resort at Pelican Hill in Newport Beach, California.
“We are excited to participate and sponsor this prestigious event,” said Lena Kannappan, Co-founder, Head of Business and Strategic Partnerships for Healthcare Triangle. “The event’s theme ‘Solving Workforce Challenges’, encompasses staffing, productivity, and AI integration, for which Healthcare Triangle specializes and provides solutions. In the ever-evolving MEDITECH landscape, our focus is on guiding the healthcare industry with the proper tools to automate, improve workflows, and innovate. We look forward to attending the Muse Executive Institute in order to both learn and provide our expertise in the dynamically changing MEDITECH environment (alt. ecosystem).”
Event Details
Event: 2024 MUSE Executive Institute
Registration link: Click here to register
Date: Jan 7, 2024, 12:00 PM (PT) - Jan 9, 2024, 01:00 PM (PT)
Location: The Resort at Pelican Hill, 22701 S Pelican Hill Rd, Newport Beach, CA 92657
HCTI Attendees:
Kelly Ziner, PMP, Principal Consultant and Manager, Healthcare Triangle
Damian David, Senior Director of Sales and Business Development, Healthcare Triangle
Attendees Bios:
Kelly Ziner, PMP, Principal Consultant and Manager, of Healthcare Triangle is a seasoned Principal Consultant in MEDITECH's web ambulatory field, having 9 years as a consultant and 11 years in MEDITECH. With expertise in implementation, integration, and optimization, she has completed 15+ successful ambulatory projects. Her profound grasp of clinical, practice management, and quality aspects empowers her to elevate operational efficiency and patient care. As a trusted MEDITECH web ambulatory consultant, Kelly stands out for her technical prowess, strategic approach, and unwavering client dedication, setting a high standard in the industry.
Damian David, Senior Director of Sales and Business Development, of Healthcare Triangle has a 23+ year career in implementing, consulting on, analysing, marketing, and delivering IT solutions to the healthcare industry. He has assisted countless hospitals and organizations in adopting technologies, from EHRs to secure cloud solutions. Damian's expertise spans leadership, consulting, project management, marketing, sales, and more. His ability to effectively fuse technology and healthcare, coupled with his commitment to client success, has led to increased performance, satisfaction, and market share.
About Healthcare Triangle
Healthcare Triangle, Inc., based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, identity management, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. www.healthcaretriangle.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 28, 2023, subsequent filings and future reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Contacts
Media:
Michael Campana
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
1-800-617-9550
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.15 |
Daily Change: | 0.02 1.77 |
Daily Volume: | 16,046 |
Market Cap: | US$6.520M |
April 04, 2024 April 03, 2024 March 12, 2024 February 14, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB